BRUCE WERMUTH: Open Payments
NPI 1629104617 · CAMPBELL, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$697 in 44 payments from 13 companies in 2025. Trend: 2023 $1,960 · 2024 $1,336 · 2025 $697
Food & beverage: $697
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $85 |
| E.R. Squibb & Sons, L.L.C. | 4 | $79 |
| Lundbeck LLC | 3 | $59 |
| Neurocrine BioSciences, Inc. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Alkermes, Inc. | 2 | $40 |
| Bausch Health US, LLC | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $28 |
Products named: VRAYLAR, CAPLYTA, COBENFY, REXULTI, INGREZZA, FANAPT, INVEGA SUSTENNA, LYBALVI.
Industry payments across CA — which companies pay providers there.
